Hello, Guest
Login
Sign Up
 
 

PennyStocks101 Reports 3 TOP Stocks to Watch Closely: Amyris, Lexicon Pharmaceuticals, and Vringo

PennyStocks101.com provides its subscribers with timely information and exclusive charts on cheap and under-valued stocks in the United States with the potential of breaking out.

 
 
Repost This

Beverly Hills, CA -- (SBWIRE) -- 12/31/2012 -- http://www.PennyStocks101.com - The US leader in microcap breakouts, offers a high quality stocks alert newsletter to investors looking for the best breakout stocks around. PennyStocks101 reports 3 penny stocks to keep an eye on for a possible bounce or more gains: AMRS, LXRX, and VRNG

The market traded choppy on Monday as investors wait for a fiscal cliff resolution. The Dow Jones industrial average surged as much as 99 points in midday trading, but by 2 p.m. the Dow was up 34 points at 12,973.

1. Amyris (NASDAQ:AMRS) - Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories.

2. Lexicon Pharmaceuticals (NASDAQ:LXRX) - Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology.

3. Vringo (NYSE:VRNG) - Vringo, Inc. provides a platform that allows users to create, download and share mobile entertainment content in the form of video ringtones for mobile phones.

Pennystocks101.com educates and shows investors the inner workings of the volatile world of penny stocks by scouring the markets for the hottest penny stocks that look poised to break out. Discover the next hidden company to profit. Sign up for the free newsletter to receive the next big report soon. Join at: http://www.PennyStocks101.com

Sign Up at - http://www.PennyStocks101.com for more ideas to put on your radar.

Disclosure
Pennystocks101.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. This press release may contain several forward looking statements. Please read our report and visit our website for complete risks and disclosures.